Antibodies recognizing a carbohydrate containing epitope on CD-43 and CEA expressed on cancer cells and methods using same
    2.
    发明授权
    Antibodies recognizing a carbohydrate containing epitope on CD-43 and CEA expressed on cancer cells and methods using same 有权
    识别在癌细胞上表达的CD-43和CEA上的含碳水化合物表位的抗体及使用其的方法

    公开(公告)号:US07674605B2

    公开(公告)日:2010-03-09

    申请号:US11811303

    申请日:2007-06-07

    IPC分类号: C12P21/08

    摘要: The present invention provides novel antibodies specifically bind to an epitope on CD43 and CEA expressed on nonhematopoietic cancer cells, but do not specifically bind to a CD43 expressed by a leukocyte or by a Jurkat cell, and is capable of inducing apoptosis of the nonhematopoietic cancer cell after binding to the epitope on cell surface of the nonhematopoietic cancer cell in the absence of cytotoxin conjugation and immune effector function, wherein the epitope comprises a carbohydrate structure and the binding of the antibody to the epitope is inhibited by a carbohydrate comprising a Lea structure, a Lea-lactose structure, a LNDFH II structure, or a LNT structure. In addition, the present invention also provides use of the antibodies described herein for diagnostic and therapeutic purposes.

    摘要翻译: 本发明提供了特异性结合在非造血癌细胞上表达的CD43和CEA上的表位的新型抗体,但不特异性结合由白细胞或Jurkat细胞表达的CD43,并能够诱导非造血细胞的细胞凋亡 在不存在细胞毒素缀合和免疫效应子功能的情况下在与非造血细胞癌细胞的细胞表面上的表位结合之后,其中所述表位包含碳水化合物结构,并且抗体与表位的结合被包含Lea结构的碳水化合物所抑制, Lea-lactose结构,LNDFH II结构或LNT结构。 此外,本发明还提供本文所述的抗体用于诊断和治疗目的的用途。

    Prostaglandin reductase inhibitors
    6.
    发明申请
    Prostaglandin reductase inhibitors 审中-公开
    前列腺素还原酶抑制剂

    公开(公告)号:US20090124688A1

    公开(公告)日:2009-05-14

    申请号:US11650868

    申请日:2007-01-08

    IPC分类号: A61K31/215 C12N9/99 A61K31/19

    CPC分类号: A61K31/353

    摘要: A method of inhibiting 15-keto prostaglandin-Δ13-reductase 2 by contacting 15-keto prostaglandin-Δ13-reductase 2 with an aryl compound of Formula (I), (II), (III), or (IV) shown herein. Also disclosed are methods of treating peroxisome proliferators-activated receptor related diseases and lowering blood glucose levels by administering to a subject in need thereof an effective amount of such an aryl compound.

    摘要翻译: 通过使15-酮前列腺素-Δ13-还原酶2与本文所示的式(I),(II),(III)或(IV)的芳基化合物接触来抑制15-酮前列腺素-Δ13-还原酶2的方法。 还公开了通过向有需要的受试者施用有效量的这种芳基化合物来治疗过氧化物酶体增殖物激活受体相关疾病并降低血糖水平的方法。